Spironolactone in Diabetic Nephropathy

• Status: Completed
• Trial end date: 2005-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of the study was to evaluate the renoprotective effect (i.e. albuminuria- and bloodpressure lowering effect) of spironolactone 25 mg o.d. in type 1 and type 2 diabetic patients with albuminuria despite recommended antihypertensive treatment.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Steno Diabetes Center; Steno Diabetes Center Copenhagen
• Treatments: Spironolactone

Criteria

Inclusion Criteria:

• Diabetes Mellitus

• Diabetic Nephropathy

• Glomerular filtration rate > 30 ml/min/1.73 m2

• Blood pressure > 130/80 mm Hg

Exclusion Criteria:

• Child bearing potential

• Plasma-potassium >4.5 mmol/l

• Breastfeeding

• Abuse of alcohol or drugs

• Non-diabetic kidney disease